Cronos Group Inc. (CRON) Earnings Call Transcript & Summary
March 30, 2020
Earnings Call Speaker Segments
Operator
operatorGood evening, everyone. I’m Ryan, and I’ll be serving as your conference operator for today. I want to welcome all of you to the Cronos Group 2019 Fourth Quarter and Full Year Earnings Conference Call. This call is being recorded today. At this point, I’ll hand things over to Anna Shlimak from Investor Relations. Anna, please go ahead.
Anna Shlimak
executiveThank you, Ryan, and thanks to everyone for being with us today as we go over Cronos Group's financial and business results for the 2019 fourth quarter and the full year. With me on the call are our Chairman, President, and CEO Mike Gorenstein; our CFO, Jerry Barbato; and Xiuming Shum, EVP, Legal and Regulatory Affairs. Cronos Group has put out a news release announcing our financial results, and those are filed on our EDGAR and SEDAR profile. That information, along with the prepared remarks, will also be posted on our website under Investor Relations. Before handing the call to Mike, I want to remind you that what we discuss on this conference call will include forward-looking statements. Those statements rest on assumptions that carry risks and uncertainties, and those could make actual results differ materially from what the forward-looking statements project, including because of the factors laid out in the cautionary statement and risk factors contained in the company's earnings release and regulatory filings, including the company's most recent annual report on Form 10-K, by which any forward-looking statements made during this call are qualified in their entirety. Also, during this call, we may discuss certain financial measures that are not recognized under U.S. generally accepted accounting principles, which the Securities and Exchange Commission refers to as non-GAAP measures.
Anna Shlimak
executiveWe think these non-GAAP measures are useful for management and planning, forecasting, and evaluating how the business and finances are performing, including when allocating resources. You can find reconciliations of these non-GAAP measures to the closest reported GAAP measures in our earnings press release furnished to the SEC. I'd also like to mention that we're conducting today's call from our respective remote locations. Because of that, there may be brief delays, crosstalk, or minor technical issues during this call. We thank you in advance for your patience and understanding. We will now make prepared remarks, and after that we'll move to a question-and-answer session. With that, I'll pass it over to Cronos Group’s CEO, Mike Gorenstein.
Mike Gorenstein
executiveThank you, Anna, and good afternoon to all of you. We are clearly in a period unlike anything we've seen before, and we're working hard to adjust to the circumstances we now face and to get the most out of the difficulties in front of us. I hope each person listening is remaining safe and well, and in a bit I'll discuss the steps we're taking in reaction to COVID-19. To begin, I'd like to cover recent events concerning our financial reporting and internal controls, along with the remediation efforts we're pursuing following our review. We have finished a comprehensive examination of our financials and controls, and we're dedicated to setting things right and putting the strongest financial reporting practices in place. My thanks go to our finance team and advisors, who collaborated closely with us across the past few weeks to complete this work. As you're aware, the Audit Committee of the Cronos Group Board of Directors recently carried out a review of certain bulk resin purchases and sales of products through the B2B wholesale channel. After that review concluded, and acting on the Audit Committee's recommendation together with advice from our independent auditor, KPMG, Cronos decided to restate our unaudited interim financial statements for the first, second, and third quarters of 2019.
Mike Gorenstein
executiveAs a result, revenue for the quarter that closed on March 31, 2019 was lowered by CAD$2.5 million, and for the quarter that closed on September 30, 2019, the reduction came to CAD$5.1 million. These issues matter to us greatly, and there are a few points I'd like to spell out. The matters in question involve three transactions tied to the wholesale B2B channel. Given the strategic initiatives currently in progress, we don't see this segment as a core growth engine for the business. We learned that these transactions warranted a review through our internal reporting processes and the avenues available for people to voice concerns, and it's gratifying that the process functioned the way it was designed to. Looking at the broader picture and where we're headed, these transactions have no bearing on our capacity to carry out our strategy and generate long-term value for shareholders. With the review now finished, we're implementing comprehensive measures to sharpen our internal policies and procedures and reinforce internal controls, financial reporting among them. We expect it will take a number of quarters to put these steps in place. Allow me to detail some of these actions. To begin, we're putting measures in place to separate duties across sales and purchase transactions. As part of that effort, we're revising internal policies within our sales and supply chain departments, constructing comprehensive customer and vendor databases, and rolling out training and education programs on revenue recognition for staff in those teams.
Mike Gorenstein
executiveNext, we're strengthening the controls and procedures we have in place for non-routine transactions, particularly when it comes to wholesale B2B deals. So to do that, we will now require teams to know about and produce accounting memorandums containing the key details of each transaction, put together business cases that set out what the transaction is for, and seek approval from Jerry or from me. We're also going to improve our certification process so employees have a clearer understanding of these transactions and the way they affect our financial results. And third, we're upgrading our quarterly risk assessment and control processes so they reflect the changes in our business. We are dedicated to setting things right and putting best practices in place for financial reporting. As a company that is growing within an industry that is rapidly evolving, over the last year we have taken a number of steps to strengthen our internal capabilities and bring in additional resources across functions in support of our strategic growth initiatives. As you're aware, my focus, and the company's focus, is on generating long-term shareholder value through the development of disruptive intellectual property and the building of iconic brands. I encourage long-term thinking, and I do not tolerate or incentivize short-termism. Our value is going to come from technology breakthroughs and from branded sales that help us build and strengthen our relationship with consumers. Before we get into the results and company updates, I'd like to address the evolving COVID-19 situation and the necessary changes Cronos Group has made to our business during this unprecedented time.
Mike Gorenstein
executiveSafeguarding the well-being and security of the people who work for us and the people who buy from us, along with making sure our supply chain stays secure, remains at the very top of our list. I personally head a worldwide, cross-functional internal task force that we put together, and it has been watching developments on a daily basis very carefully. Alongside that, the Company has continuity plans for the business in place that support our employee base, even as we keep creating and manufacturing dependable, high-quality goods that satisfy what our consumers need. As of today, our manufacturing facilities are still open, since governments in the regions where we operate have classified our business as essential. For certain employees, we have put work-from-home policies in place, together with a strict policy of no travel, including travel between our sites. At our manufacturing facilities, we have strengthened hygiene and sanitation practices, adjusted schedules, and kept social distancing protocols in place. Because circumstances differ by region and by country, we are working hard to keep acting in line with all applicable guidance from local, federal, and international health and governmental authorities, and we stand ready to make further operational adjustments if needed. Even with our business continuity efforts, certain parts of our business—operational capacity or supply chain delays, for instance—may feel an impact, yet we will stay vigilant as we evaluate the situation while it unfolds, and we will keep making decisions grounded in what is best for our company, our employees, and our customers.
Mike Gorenstein
executiveWe recognize that consumers are depending on us right now, and we are meeting that challenge in a responsible way. So with that said, let's examine more closely how much progress our strategy has delivered during the past quarter as we keep building the foundation for growth over the long term. I'll begin with what we achieved in establishing and growing our portfolio of brands. Our aim is to deliver consistent, high-quality cannabinoid products to the market while also broadening the ways consumers engage with and shop in this category. Back in fall 2019, we brought the luxury hemp-derived CBD brand Lord Jones into our brand portfolio and welcomed that talented, creative team into the Cronos family. Now, under the Lord Jones brand, we manufacture, market, and distribute hemp-derived, CBD-infused skincare and other personal care products in the U.S. market through e-commerce and retail outlets including Sephora, SoulCycle, and Neiman Marcus. Over the holiday season, Lord Jones tested its own retail approach by running three holiday pop-up shops at the Westfield holiday markets. That let us see how a larger retail concept could work and taught us about consumer habits during the holidays. We look forward to bringing this brand, along with other skincare brands and products, to more consumers in 2020.
Mike Gorenstein
executiveDuring the prior quarter, we announced the introduction of PEACE+, which is a new hemp-derived CBD brand here in the U.S. We're really excited now to be bringing that brand to market. We've chosen to take a careful, measured approach when it comes to distributing the hemp-derived CBD tinctures product line. So with that in mind, we made the decision to pause distribution of PEACE+ hemp-derived CBD tinctures through the Altria sales and distribution network while we gather additional information and evaluate the changing environment. Cronos is still dedicated to satisfying what adult consumers want, and we'll keep assessing other product formats and categories that we think might fit the PEACE+ brand better given the current and evolving climate. As we enter new markets, trade channels and product formats, and as we launch new brands, we stay fully committed to doing all of that responsibly. To establish that standard and take on a leadership position, at times we'll make tough calls in the near term, but we believe this course will put us as the market leader over the long term. We keep welcoming open dialogue and collaboration, and we look forward to working alongside industry peers, regulators and governments so that reasonable regulation can prevail. We are dedicated to making sure consumer education, science, research and higher standards for cannabis consumer products keep advancing across every market we serve.
Mike Gorenstein
executiveWhen it comes to the Canadian 2.0 market, we introduced new vaporizer offerings under our adult-use brands, Spinach and COVE. Our premium brand COVE brought out an elegant vaporizer pen, and the Spinach line drew inspiration from highly sought-after strain-specific terpene profiles, shaped through consumer insight research; both arrived on shelves in late December of last year. Considerable effort went into preparing the launch of these vaporizer products, and while we began with non-proprietary hardware in the Canadian market, that was a deliberate choice, since we recognize that consumers are still in a trial phase when a market is new. A consumer-first approach guides everything we do, and that is reflected directly in the new tailored 510 vaporizer product lines for COVE and Spinach. We partnered with Cronos Device Labs to deliver the strongest version of this product to market. Quality stainless-steel components, food-grade silicone, and tamper resistance are what our cartridges are built with. We devoted months to due diligence, working on the ground with our suppliers, to make sure the products released to market were properly tested before launch. Contemporary, intuitive designs define our rechargeable draw batteries, which incorporate mechanisms to prevent overheating. And premium cannabis extract with all-natural, terpene-rich flavors is what our formulations are made with.
Mike Gorenstein
executiveOur commitment to quality is uncompromising, and that commitment sits at the core of all our operations. As we keep gathering deeper consumer insights regarding the Canadian market, we're eager to create innovative, differentiated products that address what our consumers need and go beyond what they expect. Moving to distribution: in the Canadian market during Q4, we broadened our distribution network and started selling products to cannabis control authorities in Manitoba, New Brunswick and Quebec. Through its adult-use brands, COVE and Spinach, Cronos today sells dry flower, pre-rolls, cannabis oils and cannabis vapes to the cannabis control authority in Ontario, British Columbia, Alberta, Nova Scotia, and Prince Edward Island, and also to private-sector retailers in Saskatchewan. We strongly believe that the optimal route to generating value across the supply chain is partnering with contract farmers and suppliers to cover our capacity requirements, rather than constructing our own cultivation to serve those requirements. We keep shaping our supply chain for efficiency and flexibility, always with the best interests of our business in mind, aiming to establish a global network of co-manufacturing and contract farming alongside first-class operating partners. Toward that goal, and during the fourth quarter, we continued building out and transitioning certain facilities at the Peace Naturals campus to provide for additional R&D activities along with the production and manufacturing of derivative products.
Mike Gorenstein
executiveWe feel good about how the redesign was coming along and see it as a logical next step for our company as we seek to advance and generate efficiencies at our sites. Progress also continues at our production and manufacturing operation abroad in Israel, where we are getting nearer to being ready to operate. At that site, we collaborate closely with our partners at Kibbutz Gan Shmuel and can draw on their farming know-how along with their skilled workforce and substantial infrastructure, such as warehousing, utilities and much more. In December of 2019, Cronos Israel passed full Good Agricultural Practices audits covering propagation and cultivation, plus GMP and Good Distribution Practices inspections of the manufacturing and distribution facilities. Those licenses let us grow, produce and sell products in Israel. We are now awaiting official GMP certification for the site, which is anticipated to come in stages during 2020 for flower, pre-rolls and oil. We look forward to pursuing our GMP certifications and bringing Peace Naturals products to the Israeli medical market later this year. Looking back on 2019, one area where I believe we achieved exciting progress is our intellectual property efforts and our dedication to putting money into advanced, breakthrough technologies that we expect could have the potential to disrupt our industry as well as others.
Mike Gorenstein
executiveWe feel good about the headway we were making in our research partnership with Ginkgo, which will enable us to manufacture cultured cannabinoids at commercial scale. Certain patent applications connected to cannabinoid fermentation have been filed by Ginkgo in order to safeguard intellectual property created through the research advancing within our partnership. Cronos Group, under this partnership, holds the exclusive license to the intellectual property covered by those patent applications for the target cannabinoids. In November, we welcomed the employees of Cronos Fermentation, a group that includes engineers, scientists, and production and quality assurance personnel who were previously employed by Apotex Fermentation. Our belief is that Cronos Fermentation will let us speed up our breakthrough technology initiative by refining the cannabinoid fermentation manufacturing process ahead of a commercial scale rollout. Work has begun at Cronos Fermentation on developing scale up and downstream processes, and at the same time Ginkgo is developing microorganisms for producing cultured cannabinoids; as Cronos advances the processes and parameters, those learnings will be applied to the strains that will be used for commercial production of cultured cannabinoids. The R&D license has been received by Cronos Fermentation, and it is awaiting receipt of our production licenses, which commercialization of cannabinoids at the facility requires.
Mike Gorenstein
executiveTo put it briefly, we feel great about what we've achieved so far, and we're eager to launch this disruptive technology once it's ready. Before I wrap up, I want to look back on what an amazing year it's been. We tend not to dwell on everything we managed to pull off and how quickly we grew in such a brief window, yet it's worth remembering all that was done to get us where we stand now. A few of 2019's headline achievements: we completed a $1.8 billion investment from Altria and started drawing on Altria's know-how in manufacturing, product development and a great deal more. We're excited to keep collaborating with Altria as together we build the cannabinoid industry. We launched an R&D-focused initiative, Cronos Device Labs, which pairs a talented research and product development team with substantial vaporizer expertise, and that team is spearheading the creation of next-generation vaporizer products. We brought on Dr. Todd Abraham as Chief Innovation Officer, and he contributes more than 35 years of R&D in consumer product experience to cannabinoid research and innovation. We purchased a pharmaceutical fermentation facility to push forward our research with Ginkgo and ultimately to produce cultured cannabinoids at commercial scale for the Canadian market.
Mike Gorenstein
executiveWe also made our entry into the U.S. market through the acquisition of Lord Jones, a premium hemp-derived CBD brand, and we welcome their talented team into the Cronos family. All in all, we believe the company is being positioned for long-term success through investment in innovation, R&D, and brands. Sustainable growth is the focus of our strategy, and we believe that what we are building will create long-term shareholder value. With that, I'll hand things over to Jerry for a discussion of this quarter's financial results.
Jerry Barbato
executiveThanks, Mike, and good morning, everyone. I'll walk you through the specifics of how we performed in the fourth quarter and for the whole of 2019. Every number I'll go over today appears in the 10-K we filed with the SEC. Before that, though, let me restate a few of the key points Mike raised earlier about the restatement. The Board of Directors and the whole management team here at Cronos Group treat this issue with the utmost seriousness. We carried out a comprehensive review of our financials and our internal controls. I want to express my appreciation to our finance team and our advisors, who put in tremendous effort to finish that review promptly. We're taking wide-ranging steps to sharpen our internal policies and procedures and to bolster internal controls, financial reporting among them, and we're dedicated to best practices. That involves putting the following steps in place. First, we're making sure duties are segregated when it comes to sales and purchase transactions. Second, we're upgrading our controls and procedures for non-routine transactions, particularly wholesale sales and purchases. And third, we're improving our quarterly risk assessment and control processes so they reflect shifts in our business. We've consistently said over the past year that drawing and keeping the right talent in the right areas ranks among our top priorities, which will help us get ready for our future growth initiatives, and we'll keep at it to strengthen our infrastructure.
Jerry Barbato
executiveImproving our internal controls and financial reporting practices sits at the top of our list. Work on these efforts has already begun, and I am confident that this undertaking will leave us even stronger. Before we get into financial performance, I want to offer a few remarks on our move to U.S. GAAP reporting, our filing—including the press release—and, more broadly, how we conduct the business. As I noted in last quarter's remarks, Cronos began filing domestic SEC reports as of January 1, 2020, and our financial results are now reported under U.S. GAAP, with the U.S. dollar as our reporting currency. Historical financial information appears in our 10-K filing, which is currently available on EDGAR and SEDAR. On the conversion to U.S. GAAP, the biggest change relative to IFRS concerns biological asset accounting, which does not exist under U.S. GAAP. Under U.S. GAAP, agricultural products are carried on the balance sheet at the lower of cost or net realizable value, whereas IFRS accounts for these products at fair value, less estimated selling costs. We have also updated our financial disclosures and reporting structure to reflect how we are managing the business. Going forward, we will discuss our business with two segments, U.S.
Jerry Barbato
executiveAnd Rest of World. Finally, operating income is now the measure we use to assess performance and decide how resources get allocated among our business segments. Many industries, CPG and consumer staples included, rely on operating income as their metric. You might recognize this metric under different labels, such as income from operations or operating profit. I'd like to take a moment to walk through this measure and explain why we consider it helpful for understanding how our business is performing. Operating income, or loss, is net revenue minus cost of sales and operating expenses. At the segment level, corporate expenses are left out of operating income, since they don't directly affect a segment's underlying performance. In our view, operating income gives the clearest picture of the segments' core business performance relative to other metrics, because it does not exclude depreciation or amortization of revenue generating assets. Those revenue generating assets carry a real economic cost, and measuring business performance through EBITDA, which excludes these items, represents results that are not reflective of our underlying business performance. Our asset-light strategy requires that our segment managers stay ever vigilant and financially disciplined about their capital expenditures. By measuring and discussing our performance in terms of operating income, we believe we hold our segment managers accountable for their investments and accurately reflect the merits of our asset-light strategy.
Jerry Barbato
executiveWe look at these results on an adjusted basis. That basis leaves out certain special income and expense items, which can be highly variable, unusual, or infrequent and can distort the underlying business trends and results. In a press release, we've included a section giving information and details on the special items for this quarter and for the year-end comparison periods for 2018. We've also included reconciliation tables in our press release and 10-K that bridge the reported GAAP operating loss to the adjusted operating loss for each of our segments. Moving to Q4 results, most of my comments will focus on how the fourth quarter performed versus the fourth quarter of 2018, which is a slight change from the sequential discussion in prior quarters. The company reported net revenue of $7.3 million in the fourth quarter, a 71% increase from prior year. Revenue growth for the quarter was driven primarily by distribution of vaporizer products in Canada and by the inclusion of financial results for the Redwood acquisition. In the Rest of World segment, reported net revenue for the fourth quarter of 2019 was $4.6 million, an increase of 8% from the fourth quarter of 2018. That is primarily driven by the continued expansion of growth in the adult-use business in Canada and by the introduction of vaporizer products in the fourth quarter of 2019.
Jerry Barbato
executiveFor the Rest of World segment, gross margins came in negative during the fourth quarter, down from the fourth quarter of 2018, with the main driver being inventory write-downs in 2019. In Q4 we took an inventory write-down of roughly $24 million, which consisted of a one-time charge of $1.9 million tied to repurposing certain facilities at the Peace Naturals Campus, plus a $22.1 million write-down on cannabis oil and flower. Adjusting for the impact of those inventory write-downs, Q4 gross profit would have come to $2.2 million, which works out to gross margins of 48%. That said, we do expect further inventory write-downs near term, given pricing pressures in the marketplace and as the company carries out its operational repurposing of the Peace Naturals Campus. Operating expenses for the Rest of World segment were $37.3 million in the fourth quarter of 2019, an increase of 247% versus the fourth quarter of 2018. The main driver of that increase is higher sales and marketing costs, tied to agency and market research fees related to the adult-use markets. G&A growth came from an increase in headcount, along with various professional and consulting fees. Repurposing costs at the Peace Naturals Campus account for $5.3 million of the growth, and R&D expenses rose mainly because of costs associated with Ginkgo.
Jerry Barbato
executiveFor the Rest of World segment, the adjusted operating loss came to $51.8 million in Q4 2019. That was a substantial increase over the fourth quarter of 2018, mainly because of an inventory write-down and higher operating costs, partly offset by higher net revenue. In Q4, the U.S. segment posted net revenue of $2.7 million, as Redwood keeps growing distribution of Lord Jones products both in retail and via e-commerce channels. Gross margin for that segment was strong at 53%, driven by Lord Jones' position in the super premium luxury CBD category. The segment posted an adjusted operating loss of $1.8 million in the fourth quarter of 2019. That loss stemmed mainly from higher marketing costs tied to continued expansion of Lord Jones products as well as upcoming new product and brand launches. On an overall basis, Cronos reported higher net income than the prior year, chiefly because of the change in fair value of the financial derivative liability tied to Altria's investment, which the 10-K describes in more detail. During the fourth quarter, the company booked a non-cash gain of $118.8 million connected to the change in fair value of those financial derivative liabilities.
Jerry Barbato
executiveCronos still anticipates that reported earnings could swing substantially, mainly because of fair value adjustments each quarter tied to movements in Cronos Group’s stock price. Now on the balance sheet: the company finished the quarter with roughly $1.5 billion in cash and short-term investments, basically flat versus the third quarter. Full-year capital expenditures came to $39 million. That outlay covers investments in our Peace Naturals Campus, Cronos Fermentation, our Israeli facility, and device technology innovation at Cronos Device Labs. Our focus stays on putting capital to work in a disciplined way and solely where it matches our strategic priorities. I also want to update you on the redesign at our Peace Naturals Campus that we announced last quarter. We are optimizing our Peace Naturals Campus for alternative uses such as R&D facilities and derivative product manufacturing. Since our last earnings call, we have taken rooms out of cultivation across a number of buildings at the Peace Naturals Campus and started transitioning space for R&D and derivative manufacturing. In the fourth quarter, we booked a total pre-tax one-time charge of $7.2 million tied to the repurposing efforts at the Peace Naturals Campus, with $1.9 million linked to an inventory write-down and $5.3 million of operating expenses, mostly related to impairment costs.
Jerry Barbato
executiveAll in all, we feel good about the strategic strides the business achieved in 2019. That year involved transition and substantial investment aimed at reaching our long-term objectives. We anticipate continuing to put money behind our strategic initiatives across both the U.S. and Rest of World segments. We recognize this won't come easily, yet I feel optimistic regarding our plans for 2020 and beyond to secure long-term leadership within the cannabis space. With that said, I'll hand things to Mike for closing remarks ahead of Q&A.
Mike Gorenstein
executiveThanks, Jerry. Cannabis is a young sector, and plenty of potential opportunities lie ahead of it. Over the past few years, capital was cheap, assets were pricey, and both the product formats on offer and distribution were limited. 2019 was truly the first year of broad adversity for the industry. During 2020, that pattern has persisted, adding macroeconomic headwinds across the globe that demand changes in how people interact with each other and conduct business. In our industry right now, capital costs more and assets cost less, even as distribution is starting to open up and new product formats are coming to market. Our long-term thesis on cannabis remains unchanged. And we believe that with our strong balance sheet, our investments in disruptive intellectual property, and the flexibility our asset-light model gives us, we are well positioned to act opportunistically and aggressively capture opportunities in the near, medium and long term. With that, let's open the line for questions now.
Operator
operatorOur first question is now coming from John Zamparo, who's on the line from CIBC.
John Zamparo
analystThanks. Good afternoon. I'd like to ask about disruption to the Lord Jones business — presumably SoulCycle and Sephora locations across the U.S. are closed. But it looks like there could be some restrictions affecting the Lord Jones website. So I'm just wondering, will those stay in place for as long as shelter-in-place rules remain in effect in California? And could you speak broadly about how big the DTC business at Lord Jones is compared with brick-and-mortar stores?
Mike Gorenstein
executiveAbsolutely. Thanks — that's a really good question. Our business was recently classified as essential, so from a supply chain standpoint, we can still keep operations running. Naturally, we have to watch how things potentially play out and develop. That said, at this moment we're still able to manufacture and ship product. When it comes to DTC versus retail, these are truly unprecedented times, and it's simply too early to draw any real conclusions from the data we're looking at. Clearly, with retail — and with many categories shut down — we believe we're seeing some movement from retail toward DTC as people self-quarantine. Still, it's probably too soon to tell whether these are genuine sales trends or pantry loading rather than lasting shifts in how consumers buy. So I think we'll keep monitoring it, but we do expect that if the nationwide trends we've observed persist, a move toward online purchasing rather than brick-and-mortar is more likely.
John Zamparo
analystAll right, thank you. My follow-up question concerns PEACE+, and I'd like you to describe the current regulatory landscape for CBD. Have any encouraging developments appeared on that side? The FDA's December statement came across as fairly cautious, it seems, yet have you held discussions with the FDA that brought you to any conclusions regarding what the end result could be—whether that involves maximum potency, a preference for permitting particular products, or simply any remarks on the matter, that would be great. Thank you.
Mike Gorenstein
executiveAbsolutely. Regarding U.S. CBD and where the FDA stands, that's a topic we keep watching closely, and like any regulatory setting, we appreciate candid conversation, cooperation, and we're eager to collaborate with peers in our industry, regulators, and governments to help ensure sensible rules are in place and succeed. I'd say many of — certain trends we had been tracking in terms of the direction regulations were heading, the recent COVID events have definitely altered, I believe, where the attention of numerous government bodies sits, so there's plenty happening there that could shift based on how COVID is handled and where regulators believe they must redirect their focus.
Operator
operatorRight now, there's one more question waiting on the line, and it comes from Tamy Chen at BMO Capital Markets.
Tamy Chen
analystYeah, thanks. For my first question, I just wanted to get a handle on revenues — how are you thinking about that? At what point will it start growing in a meaningful way? It feels like things in the U.S. could still be a while off, given the regulation. So, in Canada specifically, I'm just trying to get a sense of what the challenges might be — it doesn't look like supply is an issue anymore — so I just wanted a better idea of when we should expect revenues there to really start picking up. Thanks.
Mike Gorenstein
executiveYes. With the new form factors up in Canada plus revenue from hemp-derived CBD items down in the U.S., our expectation is that the resulting sales mix will lean more heavily toward adult-use revenue and less toward the opportunistic sales we saw in Canada. And since we rolled out 2.0 products along with our vape launch late in 2019, we think that should help speed up growth in Canada.
Jerry Barbato
executiveYes. I think if we zero in on Canada specifically, store growth and 2.0 clearly matter a great deal. That said, how much of an effect COVID ends up having, or not having, is also going to matter. In Ontario, additional cannabis dispensaries have kept opening their doors even through what you might call the COVID Era. That said, even though cannabis dispensaries have been classified as an essential business in Ontario, we simply lack visibility into whether the pace of store growth going forward could be slowed by other possible delays, such as those stemming from trades or macroeconomic headwinds. At the same time, though, I think the rise in online sales we've seen lately offsets that. I think you've heard Ontario bring this up once more, though in my view we still need additional time and data before we can assess precisely how much reflects pantry loading as opposed to lasting shifts in buying behavior and in how consumers will shop while they self-quarantine. On balance, though, when we consider the position we hold and the macroeconomic backdrop, our view is this: distribution points keep opening, we anticipate competition will consolidate, and we believe that gives us greater room to be aggressive when it comes to growing the business.
Tamy Chen
analystUnderstood. All right. My follow-up question concerns Ginkgo. So, Mike, I hoped you could verify something you said a bit earlier. At this stage, has Ginkgo mostly finished the formulation work? Is the only thing left that the facility gets its production license, after which you can shift into commercialization, or does R&D formulation still have additional work remaining? Thanks.
Mike Gorenstein
executiveSure. So the formulation work is something we handle at Cronos, while Ginkgo’s efforts are providing us with strains capable of fermenting cannabinoids. How we blend those cannabinoids and which kinds of consumer products we incorporate them into—that’s specific to what we’re doing in-house at Cronos. And naturally, one difference would be that obtaining rare cannabinoids in any commercial quantity through cultivation extraction is difficult, but THC and CBD, for example, are the same cannabinoid we formulate with that we would be sourcing from supply today. Essentially, the split between what happens at Cronos Fermentation versus Ginkgo, you could view that as similar to building a cultivation facility and then implementing the processes for how you grow the product, how you harvest, how you—and how you ultimately care. At Cronos Fermentation, we’re working through those processes, while the genetics—if we think about cultivation, the genetics are being developed the same way you would breed a new plant strain. Ginkgo was essentially breeding and designing those strains that we will cultivate or ferment at Cronos Fermentation.
Mike Gorenstein
executiveDoes that answer your question?
Operator
operatorIt looks like our previous caller ran out of time, but we have another question waiting on the line from Andrew Carter of Stifel.
Andrew Carter
analystHello, thank you. Good afternoon. I simply wanted to inquire — you brought up that growth beginning to pick up substantially in Canada, and of course you noted those difficulties came to light in 2019, and at present we have what amounts to a faster-paced shakeout, so to speak. How are you viewing Canada at this point compared with the way you have viewed it across your portfolio in the past? Does an opportunity exist to put more capital into this market right now? Would that be through acquisitions? Any guidance on how you are assessing the landscape at the moment would help.
Mike Gorenstein
executiveSo I think the trends are pretty clear when it comes to how things are shaping up, with capital being harder to come by throughout the sector and, at least over the past few months and near term, distribution opportunities being limited, though they are increasing. We do expect consolidation to take hold, certainly. On M&A, our view really hasn't changed: what we're after, in the end, is either something on the brand side or something on the intellectual property side that can ultimately scale. How consumers ultimately form relationships with various brands would dictate, specifically in Canada, whether we pursue growth organically or through acquisition. But we do expect that the competitiveness for organic growth will become easier as a lot of the capital reserves at competitors get depleted, including for marketing. So ultimately, opportunities we may have looked at before, if we were to revisit them now, would certainly look more accretive, but it really comes down to whether an acquisition helps us with our relationship with the consumer and whether looking at it through organic growth rather than acquisition would be more accretive.
Andrew Carter
analystOkay. Moving to my second question, which concerns the vaporizer business you've introduced — you've clearly gotten off to quite a good beginning thanks to your supply chain, so I wanted to ask — you obviously brought up COVID-19 disruption, and there have been plenty of questions regarding the Chinese supply problems. So, my first question on that point: could you give us some sense of these device sales, specifically how much they add to your gross margin overall and to the profitability of your business? Thanks.
Mike Gorenstein
executiveYeah, I think we could split that into two categories. I think the actual — the device meaning the battery and then the cartridge, which has the actual cannabis oil in it. So, I think we look at the batteries really is more of a marketing opportunity, not something that’s supposed to drive gross margin. But we do think that the cartridges, especially given pressure in the flower side over the long-term, we expect that that’s going to be accretive especially, if we continue with the progress of ginkgo and being able to take that that technology and put it into vaporizer products. We think would change the way that we look at our business.
Jerry Barbato
executiveYes. Even though our base currently has healthy margins, we chose to outsource manufacturing to CMOs, essentially to ensure we get the product format and product type right prior to bringing it in-house, so we can dial it in and improve margins over time as well as while the market keeps fluctuating when it comes to pricing. And so we'll see how that plays out over the course of 2020.
Operator
operatorWe still have additional questions waiting. The next one comes from Rahul Sarugaser at Raymond James.
Rahul Sarugaser
analystGood evening, Mike and Jerry, and thanks so much for taking my questions. My first question really concerns the PEACE+ brand: did the rollout of the first thousand stores get started at all, and now that this product line is on hold, when do you expect it to be re-launched?
Mike Gorenstein
executiveSure, it didn’t. What I mean is that we definitely completed some steps along the way, but in the end we chose to hit pause and take another look at the landscape. As for when a different product could launch, that will hinge on how we assess the landscape and, in the end, on what creates a chance for us to satisfy consumer needs. But as we see things at this moment, retail — bringing a new brand into retail, with the COVID situation as it is, is something we’ll need to work through in terms of timing, and when we begin to see a return to normalcy is when we would start considering taking a product and placing it into a new retail location, though I think supporting a new brand on shelf in the sort of social distancing world we’re in is something that would be quite hard.
Rahul Sarugaser
analystExcellent, that’s genuinely useful. Thank you. My next question is about the timing of the tech transfer for the first pair of strains that Ginkgo developed — when do you expect that to take place over at the Winnipeg facility? And can you give any visibility into when commercial production of those first two cannabinoids is expected to begin?
Mike Gorenstein
executiveYes. I believe we’ll be in a position to share more detail on that as things develop. What I can tell you is this: our confidence remains strong regarding the schedule we set out at the time we announced the transaction — September of next year.
Operator
operatorWe have additional questions submitted online, and the next one is from Chris Carey at Bank of America.
Chris Carey
analystAppreciate it, everyone, and good evening.
Mike Gorenstein
executiveGood evening, everyone.
Chris Carey
analystSo taking a step back, it's been just over 12 months since the Altria deal closed. And honestly, I'm having some trouble grasping where Cronos is headed over the near to medium term. Lord Jones came with a hefty price tag, but clearly it's a small contributor at this point, maybe it grows over time, but definitely not yet. The U.S. CBD launch keeps getting pushed back, possibly indefinitely. It sounds like there's a repivot toward Canada adult-use — not that there was never any focus there, but it certainly seems like more of an emphasis, given that market is what you'll have in the near term. So I guess I'm trying to figure out where all this work we've been discussing starts to get commercialized, or whether 2020 is another year that kind of swatches the cash balance while many others don't focus on the long term and it becomes this very long-term type story, or if some of this work might come through fruition sooner. So maybe if we could just talk about where things are going in the near to medium term, that would be helpful for me. Thank you.
Jerry Barbato
executiveAbsolutely. I’ll begin with that first portion, specifically regarding our acquisition of Redwood. We’re genuinely enthusiastic about what lies ahead for Redwood, and we expect considerable expansion throughout our new U.S. platform. In our view, the United States offers a major opportunity for Redwood to create value for Cronos. Our choice of Redwood as the U.S. platform rested not only on the strength of Lord Jones but, even more significantly, on the impressive team that the cofounders, Rob and Cindy, have built. For competitive reasons I won’t disclose our plans, but we believe that by combining the Redwood team and front offices with existing resources, this acquisition will produce substantial returns for shareholders across the medium to long-term.
Mike Gorenstein
executiveThanks Jerry. And yes, I’ll handle the medium- and long-term part. Our perspective hasn’t really shifted, and it’s similar to what we see in other consumer categories. In the end, what drives long-term value is having a product that stands apart, and we have certain approaches to conducting research. What we learn from consumer insights research ultimately shapes our work in product development. That definitely takes time, but we don’t want to push products out quickly unless we believe we’ve got a winning product. Still, we do believe that a technology breakthrough is ultimately what will allow us to create long-term value. So we have a number of initiatives, and once we believe a product is ready and we believe we can meet consumer expectations — I think that’s the first step — then certainly financial results will follow.
Chris Carey
analystOkay, and Mike, I've raised this with you previously: how would you picture the revenue split between the U.S. and, I suppose, the rest of the world—though really more or less Canada—in 2020? And I think earlier on the U.S. was viewed as probably the larger one, but it looks to me now that maybe it's flipped once more, with the Canadian business set to be the bigger piece. I'm wondering whether you can verify that this holds in your projections, and perhaps share some perspective on how things evolve from here. It's simply the kind of situation where the vape launch becomes commercialized more quickly, where wholesale pricing has clearly fallen apart, and now you're actually able to roll out that strategy of haggling, of securing cheaper raw material to sell beneath your own branded products on the flower side. So maybe help clarify what the geographic breakdown looks like, and also what the cadence will be across 2020. Thanks for that.
Mike Gorenstein
executiveOkay, so my earlier view was that the U.S. would grow faster than the rest of the world. The crucial factor there is whether we can get into physical retail locations, and although I believe we saw some movement in October away from brick-and-mortar sales toward online, I think it will be hard, as long as the present situation continues, to keep growing faster than what we see elsewhere. Still, in the end, we continue to believe that because of how big the market is, the opportunity over time could be greater, though the pace will really hinge on the broader conditions allowing us to place various kinds of CBD products on shelves. Regarding Canada, I think a few things have shifted. Much of it depends on where the competitive set ends up and which products we can introduce, and we believe there will probably be some difficulties not only in our sector but in every sector, given what is going on with COVID. However, because of how we have structured ourselves, we believe that whenever the timing falls, we should come out of the COVID crisis in a strong position, able to be somewhat more aggressive and to keep investing behind growth opportunities.
Mike Gorenstein
executiveThat said, pinning down an exact timeline is genuinely tough, since COVID’s effects could shift when those chances for fresh growth arise and when current projects can be launched into the market.
Operator
operatorWe still have additional questions waiting on the line. The next one comes from Vivien Azer at Cowen.
Vivien Azer
analystHello, and thanks. Good evening. I wanted to explore the inventory write-down a bit further. This is clearly something that has been present across the broader landscape for quite a few months now. So I was hoping to gain a clear picture of how you’re viewing price compression in the marketplace, because to me it seems that, at least from a retail perspective, that’s really only beginning to affect the market—certainly around calendar 1Q, given when the announcements of value-priced introductions in the marketplace came out. So when you recorded the inventory write-down, is the price deflation a backward-looking view or a forward-looking one, and any color you can give on what underlies the rate of price deflation that informs the inventory write-down would be helpful. Thank you.
Jerry Barbato
executiveSure. So we feel good that our balance sheet shows the most accurate valuation of inventory as of year-end, and the write-down came from downward pressure on market prices, which have dropped below what it costs to produce that inventory. Most notably on dry cannabis, how much future write-downs will amount to is somewhat uncertain. As a result, we aren't disclosing a number at present, and consistent with U.S. GAAP standards, we review our inventory balances each quarter to make sure they reflect the lower of cost or net realizable value. And I think what we're seeing in the marketplace, as you pointed out, is a downward trend in both dry flower and the oil and resins.
Vivien Azer
analystAll right, that's useful. So to pull it together, then: if that was roughly how you saw the market as of December 31, would it be fair to think that, should calendar 1Q — which finishes tomorrow — have brought additional price deflation in the marketplace, that might potentially lead to more inventory write-downs?
Jerry Barbato
executiveThat's right.
Vivien Azer
analystAlright, thanks. A quick follow-up from my end — it feels like it was months back that I was at CAGNY alongside the Altria team. Actually, it was just a little over four weeks ago that I asked Howard Willard during the breakout about how interested Altria is in broadening distribution of the PEACE+ CBD product in the U.S. Mike, I completely understand that a large-scale rollout isn’t something you’d want to pursue right now, given everything we know today about COVID-19 — that sounds very sensible. The unfortunate reality, though, is that four to five weeks ago, that wasn’t really much of a consideration. So I’m curious whether you can share if any discussions took place with Altria regarding expanding that distribution. That’s my follow-up. Thank you.
Mike Gorenstein
executiveAbsolutely. Yes. Talks are still ongoing, and both sides are strongly dedicated to this partnership. In the end, I'd say much of the conversation and analysis stems from wanting to ensure we identify suitable product formats for today's conditions, and with all the shifts underway, simply making sure we take a responsible, long-term perspective on what the product format should be and, ultimately, how that moves forward with all of our stakeholders before we launch and broaden distribution.
Operator
operatorMoving on, our following question is from Matt Bottomley at Canaccord Genuity.
Matt Bottomley
analystYes. Good evening, and thank you for taking the questions. I just wanted to follow up on a couple of questions from earlier and take a step back toward a more macro-level strategy view for Cronos. Obviously, you are one of two companies in the Canadian sector with a defensible balance sheet during these troubling times of heightened uncertainty. But again, roughly $7 million of revenue in the quarter is certainly lagging many of your peers, particularly in the Canadian sector. And Mike, I appreciate the longer-term view versus the shorter-term view. But maybe we could dig a little deeper regarding where your capital allocation is going to go and how investors should judge Cronos over the next four quarters or so. Given everything you have going on between Ginkgo and Israel, the Hampton, the U.S., and obviously everything happening in the Canadian market, the top line still is very modest. So should we expect this to be a continued trend as you allocate capital toward the longer-term initiatives, even though there are more unknowns and risks there, or is there anything we can look at in the next couple of quarters that could be definitive things to assess Cronos's performance in the more near term rather than the long term?
Jerry Barbato
executiveYes. We don't provide forward-looking guidance when it comes to our revenue projections, and regarding capital allocation, I'd say we keep monitoring how we allocate capital so we can determine the right level for reinvesting in the business as well as for external growth opportunities. And we think we've been quite active in putting that capital to work over a relatively short period, given that the Altria investment closed last March. We've acquired Redwood Holdings, we acquired Cronos fermentation. We've launched derivative products including vaporizers, and we have a credit facility out for our GrowCo joint venture. So, we remain focused on scaling the business for future success, and we'll keep evaluating external growth opportunities as a way to deploy that capital.
Mike Gorenstein
executiveThanks, Jerry. I think one of the things we certainly weigh against external growth opportunities is also assessing organic growth opportunities. And vaporizers is a category we really believe in leaning into as we keep getting more information and data on how some other formats in Canada have been received, and we can sort of learn from what products have been put out in the market. We're leveraging some of our IP that we got from Redwood, and we'll look at other things we have in development that I don't think we're talking about years before. I will start getting other product formats out and lean into them. But we do see that even over the next few months, the opportunity that we have to really grow revenue or I think, better than they were in the past, but ultimately, we're still making sure that we take a long-term view and we're doing things that are accretive. So, we feel that the cost of revenue entering any specific opportunity isn't something that generates long-term value. It's something that will pass on. But again, given where the cost of capital for most industry participants has shifted to and looking at the pricing of different assets, we think that picture started to change and because that's opportunity for us to move over the near to medium-term.
Matt Bottomley
analystUnderstood, thanks. And a quick follow-up — very anecdotal — but I've noticed that cannabis 2.0 has launched on quite a few provincial websites, the Cronos ones, whether that's COVE or Spinach or others. Those products, I've noticed, have been a lot more relevant on those sites, and obviously nobody can really tell just from reviewing websites how much depth of supply sits behind each and every skew. But is there anything we should read into for your next quarter — that there's been an uptick in overall penetration into cannabis 2.0; obviously everyone's starting from a base of zero in the prior quarter, but it's just something I've noticed on a number of the provincial websites since cannabis 1.0, that the Cronos branded products do seem more prevalent compared to what we saw just the dry bud before at lunch.
Mike Gorenstein
executiveAbsolutely. What you're observing there, I believe, comes down to the fact that we've placed a great deal of emphasis on derivative products, and that holds true even when you look at distribution across the provinces we've moved into. We need to be certain we can support our products in each of those provinces. That's why we've broadened distribution, and ensuring we have the needed supply volume along with the correct product mix is something we treat as a priority for vaporizers, and one reason we chose to have only a single 2.0 product format on the market is so we can service it properly. So again, when we consider opportunities before us, we're putting priority on ensuring greater organic growth this year, now that we believe all these markets are opening up with additional retail stores and additional product formats.
Operator
operatorThere's a final question queued up. It's from Michael Lavery at Piper Sandler.
Michael Lavery
analystThanks. Good evening, everyone.
Mike Gorenstein
executiveGood evening.
Michael Lavery
analystYou mentioned a few bright spots this quarter — clearly the much larger revenue from Lord Jones and the rollout into three additional provinces. Alberta, of course, is a well-developed market, and it also sounds like there were some early initial vaporizer sales. But could you perhaps walk us through a postmortem on what still really caused, even following the adjustment in 3Q, a fairly substantial decline, and then maybe, along with that, help us grasp what has or hasn't shifted as we look ahead and attempt to model it out.
Mike Gorenstein
executiveYes. So following the restatement, we saw some growth in Q4 compared with Q3, and as I mentioned earlier, we aren’t providing forward-looking guidance on revenue. I think many factors are in play, particularly with COVID-19 and people going to brick-and-mortar. And I think we’ll get a better sense as the environment changes and as we see how many stores actually open up, especially in Ontario, while they’ve done, I guess you could say a fair job at beginning to open more stores. These questions still remain: will they be able to get to their intended number and satisfy the market.
Michael Lavery
analystAnd one more thing — I want to be sure I'm not mixing up the figures with the restatement in U.S. dollars, so what was your revenue number for 3Q?
Mike Gorenstein
executiveSo, we recorded a $3.8 million write-down, or a change in U.S. dollars, during Q3. That means the overall change in net revenue came to $5.7 million.
Michael Lavery
analystRight — got it. So I suppose what I'm still trying to get a handle on is where the bulk of that pressure is actually coming from. Is it pressure on share, or pressure on pricing? Or is it some mix of the two?
Mike Gorenstein
executiveI think several factors played into Q4 in terms of how results came in relative to what we had anticipated. We definitely were focused on the 2.0 launch and on leaning into vaporizers. Take Alberta, a province that's quite developed, as an example. That's something that has clearly shifted, but we had expected it to serve as a major growth driver for us. And then vaporizers were temporarily not an accepted product format, which certainly changed, but much of it came down to the timing of the 2.0 launch and how different provinces were accepting different product formats. Certainly, there's probably a peak level of congestion we've been experiencing for certain types of flower, but we do expect that it will start to clear up, although pinning down the exact timing is difficult based only on the trends we've been seeing and where we'd naturally follow those. Do we expect congestion to clear up as more stores open and competition decreases?
Operator
operatorAnd right now, we don’t have anybody else waiting to ask a question.
Jerry Barbato
executiveProvided nothing further comes up, I hope all of you remain well and secure, and we'll speak again before long.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.